{"schema_version":"secwatch.filing_event.v1","accession":"0001679363-23-000074","form_type":"8-K","ticker":null,"cik":"0001679363","company_name":"Morphic Holding, Inc.","filed_at":"2023-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.038075+00:00","generated_at":"2026-06-08T22:32:46.526686+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Morphic Q3 net loss $36.2M; CEO on medical leave; positive MORF-057 Phase 2a data","bullets":["Net loss of $36.2M ($0.73/share) vs net income $30.0M ($0.78/share) a year ago; revenue $0.","President Bruce Rogers appointed interim principal executive officer as CEO Praveen Tipirneni remains on medical leave.","Positive EMERALD-1 Phase 2a data: MORF-057 achieved primary endpoint (RHI reduction 6.4 points, p=0.0019); mMCS remission 25.7% at week 12.","Cash, equivalents, and marketable securities $725.1M, providing runway into H2 2027.","EMERALD-2 Phase 2b enrollment on track; Phase 2b for Crohn's disease expected to begin H1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001679363-23-000074","json":"https://secwatch.observer/filing/0001679363-23-000074.json","markdown":"https://secwatch.observer/filing/0001679363-23-000074.md","text":"https://secwatch.observer/filing/0001679363-23-000074.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1679363/000167936323000074/0001679363-23-000074-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1679363/000167936323000074/morf-20231101.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T22:32:46.526686+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"688d473577bbde11fd2248e60dfe6337433548e9","claim":"Morphic Holding, Inc. reported the third quarter 2023 results: revenue $0 million, net income $36.2 million, EPS $0.73 per share.","evidence_excerpt":"quarter ended September 30, 2023, was $36.2 million or $0.73 per share compared to net income of $30.0 million or $0.78 per share for the same quarter last year • Revenue was $0 million for the quarter ended September 30, 2023, compared to $2.1 million for the same quarter last year due to the conclusion of the Company’s research and development collaborations","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1679363/000167936323000074/0001679363-23-000074-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter 2023"},{"label":"Revenue","value":"$0 million"},{"label":"Net income","value":"$36.2 million"},{"label":"EPS","value":"$0.73 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"d766d4346e","claim":"Bruce N. Rogers was appointed as interim principal executive officer at Morphic Holding, Inc..","evidence_excerpt":"the Board has appointed Bruce N. Rogers, Ph.D., the Company’s President, as the Company’s interim principal executive officer until Dr. Tipirneni’s return.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1679363/000167936323000074/0001679363-23-000074-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"interim principal executive officer"}],"fact_type":"executive_change"},{"claim_id":"ec0b3598aa","claim":"Praveen P. Tipirneni changed role as Chief Executive Officer at Morphic Holding, Inc..","evidence_excerpt":"Praveen P. Tipirneni, M.D., the Company’s Chief Executive Officer and a member of the Company’s board of directors (the “Board”), is taking a temporary medical leave of absence from his role as Chief Executive Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1679363/000167936323000074/0001679363-23-000074-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"taking temporary medical leave of absence"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}